Research programme: therapeutics - RELIEF THERAPEUTICS Holding

Drug Profile

Research programme: therapeutics - RELIEF THERAPEUTICS Holding

Alternative Names: DasKloster 0014-01; DasKloster 0039-01; DasKloster 0080-01; DasKloster 0182-01; DasKloster 0228-01; DasKloster 0249-01; DasKloster 0274-01; DasKloster 0501-01; DK 0051; Gonadorelin - RELIEF THERAPEUTICS; Octreotide - RELIEF THERAPEUTICS; Proadrenomedullin - RELIEF THERAPEUTICS; Valorphin - RELIEF THERAPEUTICS

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator mondoBIOTECH
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Tuberculosis
  • Discontinued Liver cancer; Lung disorders; Lymphoproliferative disorders; Pseudomonal infections; Scleroderma

Most Recent Events

  • 22 Sep 2016 Preclinical development is ongoing for Tuberculosis (RELIEF THERAPEUTICS pipeline, September 2016)
  • 22 Sep 2016 Research programme: therapeutics - RELIEF THERAPEUTICS Holding is available for licensing as of 22 Sep 2016 (http://www.relieftherapeutics.com/further-opportunities/)
  • 22 Sep 2016 Discontinued - Preclinical for Liver cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top